Kindeva Drug Delivery and Emervax Partner on Vaccine Innovation

• Kindeva Drug Delivery and Emervax announced an exclusive partnership to develop a novel solution for vaccine delivery using microneedle patch technology and circular RNA.

• The joint innovation targets infectious diseases and selected cancers, aiming for clinical trials by 2026.

Kindeva Drug Delivery, a global CDMO and leader in drug delivery solutions, has partnered exclusively with Emervax to co-develop an advanced platform for vaccine administration. This collaboration leverages Kindeva’s solid-coated microneedle array patch and Emervax’s emxRNATM circular RNA vaccine technology, setting new benchmarks for vaccine tolerability, efficacy, and accessibility.

Kindeva has granted Emervax an exclusive licence to use its microneedle patch technology, which offers precise intradermal delivery with minimal invasiveness. According to the companies, this technology is aligned with the emxRNATM platform’s dosing needs and significantly enhances vaccine stability, reducing cold chain requirements. This breakthrough addresses critical challenges in vaccine distribution, particularly in low- and middle-income countries.

Milton Boyer, CEO of Kindeva Drug Delivery, expressed enthusiasm for the partnership, stating, “This partnership reflects a common pursuit of a step change improvement in the delivery of advanced vaccines. In harnessing the combination of Kindeva’s microneedle array patch technology with Emervax’s circular RNA platform, we are excited to work together to unlock breakthrough benefits for patients.”

Emervax’s emxRNATM platform offers a patent-protected solution demonstrating greater in vivo robustness and durability compared to traditional mRNA vaccines. Its thermostable properties simplify transportation and administration, paving the way for broader vaccine accessibility. Peter Weinstein, Co-Founder and CEO of Emervax, highlighted the benefits for manufacturers and patients alike, noting that this technology “minimizes the need for cold chain storage and simplifies vaccine administration compared to current standards of care.”

The partnership aims to combat diseases such as Yellow Fever, Ebola, Monkeypox, Tuberculosis, and selected cancers. Clinical trials for this innovative solution are expected to commence in 2026.